[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2018,68(6):394-424.
[2] 郑荣寿,孙可欣,张思维, 等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
[3] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. The Lancet Global health, 2018,6(5):e555-e567.
[4] Zhu H, Yang X, Ding Y, et al. Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia[J]. Sci Rep. 2015, 5:14503.
[5] Han X, Wang Z, Hu B, et al. Autophagy inhibition contributes to Endostar sensitization in esophageal squamous cell carcinoma[J]. Oncology letters. 2017, 14(6):6604-10.
[6] Zhong Z, Gu X, Zhang Z, et al. Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus[J]. The British journal of radiology. 2012, 85(1019):e1104-9.
[7] Randomized phase II study of recombinant human endostatin combined with definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma[J]. J Clin Oncol 33, 2015 (suppl; abstr 4035). 2015.
[8] Li W, Chen P, Zhang N, et al. Endostatin and Oxaliplatin-Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study[J]. Oncologist. 2019;24(4):461-e136
[9] 中国医师协会放射肿瘤治疗医师分会,中华医学会放射肿瘤治疗学分会,中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南(2019年版)[J].国际肿瘤学杂志,2019,46(7):385-398.
[10] HUANG J, XU JM, CHEN Y, et al. Phase 3 study of camrelizumab vs chemotherapy for locally advanced/metastatic esophageal cancer: The ESCORT Study. 2019 OESO.